Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 71

1.

Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.

Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT.

Blood. 2010 Dec 23;116(26):5983-90. doi: 10.1182/blood-2010-04-278044. Epub 2010 Oct 1.

PMID:
20889920
[PubMed - indexed for MEDLINE]
Free Article
2.

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.

Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT.

Blood. 2008 Jun 15;111(12):5654-62. doi: 10.1182/blood-2007-11-126003. Epub 2008 Feb 27.

PMID:
18305216
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.

Hong Z, Xiao M, Yang Y, Han Z, Cao Y, Li C, Wu Y, Gong Q, Zhou X, Xu D, Meng L, Ma D, Zhou J.

Carcinogenesis. 2011 Oct;32(10):1550-8. doi: 10.1093/carcin/bgr176. Epub 2011 Jul 29.

PMID:
21803735
[PubMed - indexed for MEDLINE]
Free Article
4.

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ.

Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6.

PMID:
21734239
[PubMed - indexed for MEDLINE]
Free Article
5.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

PMID:
22826565
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.

Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, Min YH.

J Pharmacol Exp Ther. 2010 Nov;335(2):389-400. doi: 10.1124/jpet.110.169367. Epub 2010 Aug 10.

PMID:
20699435
[PubMed - indexed for MEDLINE]
Free Article
7.

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.

Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.

J Hematol Oncol. 2013 Feb 18;6:18. doi: 10.1186/1756-8722-6-18.

PMID:
23415012
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice.

Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E, Piacibello W, Caione L, Migliardi G, Ricciardi MR, Tafuri A, Romano M, Salati S, Di Virgilio F, Ferrari S, Baccarani M, Ferrari D, Lemoli RM.

Blood. 2012 Jan 5;119(1):217-26. doi: 10.1182/blood-2011-07-370775. Epub 2011 Nov 3.

PMID:
22053107
[PubMed - indexed for MEDLINE]
Free Article
9.
10.

Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.

Janus A, Linke A, Cebula B, Robak T, Smolewski P.

Anticancer Drugs. 2009 Sep;20(8):693-701. doi: 10.1097/CAD.0b013e32832e89b4.

PMID:
19584709
[PubMed - indexed for MEDLINE]
11.

Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.

Sen S, Hassane DC, Corbett C, Becker MW, Jordan CT, Guzman ML.

Exp Hematol. 2013 Sep;41(9):799-807.e4. doi: 10.1016/j.exphem.2013.04.012. Epub 2013 May 6.

PMID:
23660068
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.

Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD.

Leukemia. 2011 Apr;25(4):606-14. doi: 10.1038/leu.2010.294. Epub 2011 Jan 14.

PMID:
21233840
[PubMed - indexed for MEDLINE]
13.

A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.

Wang W, Adachi M, Zhang R, Zhou J, Zhu D.

Pancreas. 2009 May;38(4):e114-23. doi: 10.1097/MPA.0b013e3181a0b6f2.

PMID:
19342982
[PubMed - indexed for MEDLINE]
14.

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.

Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA.

Leukemia. 2010 Apr;24(4):687-98. doi: 10.1038/leu.2010.32. Epub 2010 Mar 4.

PMID:
20200557
[PubMed - indexed for MEDLINE]
15.

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtjärn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML.

Leukemia. 2013 Mar;27(3):560-8. doi: 10.1038/leu.2012.256. Epub 2012 Sep 3.

PMID:
22940834
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J.

Leukemia. 2012 Jun;26(6):1266-76. doi: 10.1038/leu.2011.392. Epub 2012 Jan 13.

PMID:
22289989
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Identification of AML1-ETO modulators by chemical genomics.

Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K.

Blood. 2009 Jun 11;113(24):6193-205. doi: 10.1182/blood-2008-07-166090. Epub 2009 Apr 17.

PMID:
19377049
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.

Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT.

Blood. 2005 Jun 1;105(11):4163-9. Epub 2005 Feb 1.

PMID:
15687234
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes.

Spence T, Perotti C, Sin-Chan P, Picard D, Wu W, Singh A, Anderson C, Blough MD, Cairncross JG, Lafay-Cousin L, Strother D, Hawkins C, Narendran A, Huang A, Chan JA.

Neuro Oncol. 2014 Jan;16(1):62-71. doi: 10.1093/neuonc/not162. Epub 2013 Dec 4.

PMID:
24311633
[PubMed - indexed for MEDLINE]
20.

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.

Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Blood. 2010 Nov 18;116(20):4262-73. doi: 10.1182/blood-2010-02-269837. Epub 2010 Jul 28.

PMID:
20668229
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk